Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/45916
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZhang, Dong-Yan-
dc.contributor.authorAn, De-Wei-
dc.contributor.authorYu, Yu-Ling-
dc.contributor.authorMelgarejo, Jesus D-
dc.contributor.authorBoggia, José-
dc.contributor.authorHansen, Tine W-
dc.contributor.authorMARTENS, Dries-
dc.contributor.authorAsayama, Kei-
dc.contributor.authorOhkubo, Takayoshi-
dc.contributor.authorStolarz-Skrzypek, Katarzyna-
dc.contributor.authorMalyutina, Sofia-
dc.contributor.authorCasiglia, Edoardo-
dc.contributor.authorLind, Lars-
dc.contributor.authorMaestre, Gladys E-
dc.contributor.authorWang, Ji-Guang-
dc.contributor.authorImai, Yutaka-
dc.contributor.authorKawecka-Jaszcz, Kalina-
dc.contributor.authorSandoya, Edgardo-
dc.contributor.authorRajzer, Marek-
dc.contributor.authorNAWROT, Tim-
dc.contributor.authorO’Brien, Eoin-
dc.contributor.authorYang, Wen-Yi-
dc.contributor.authorFilipovský, Jan-
dc.contributor.authorGraciani, Auxiliadora-
dc.contributor.authorBanegas, José R-
dc.contributor.authorLi, Yan-
dc.contributor.authorStaessen, Jan A-
dc.date.accessioned2025-05-08T12:42:45Z-
dc.date.available2025-05-08T12:42:45Z-
dc.date.issued2025-
dc.date.submitted2025-04-22T07:59:24Z-
dc.identifier.citationEuropean heart journal,-
dc.identifier.issn0195-668X-
dc.identifier.urihttp://hdl.handle.net/1942/45916-
dc.description.abstractBackground and Aims Downloaded from https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf220/8116060 by Hasselt University user on 08 May 2025 Hypertension is the predominant modifiable cardiovascular risk factor. This cohort study assessed the association of risk with the percentage of time that the ambulatory blood pressure (ABP) is within the target range (PTTR) proposed by the 2024 European Society of Cardiology (ESC) guidelines for blood pressure (BP) management.Methods In a person-level meta-analysis of 14 230 individuals enrolled in 14 population cohorts, systolic and diastolic ABPs were combined to assess 24-h, daytime, and nighttime PTTR with thresholds for non-elevated ABP set at <115/65, <120/70, and <110/60 mmHg, respectively. Results Median 24-h PTTR was 18% (interquartile range 5–33) corresponding to 4.3 h (1.2–7.9). Over 10.9 years (median), deaths (N = 3117) and cardiovascular endpoints (N = 2265) decreased across increasing 24-h PTTR quartiles from 21.3 to 16.1 and from 20.3 to 11.3 events per 1000 person-years. The standardized multivariable-adjusted hazard ratios for 24-h PTTR were 0.57 (95% confidence interval 0.46–0.71) for mortality and 0.30 (0.23–0.39) for cardiovascular endpoints. Analyses of daytime and nighttime ABP, cardiovascular mortality, coronary endpoints and stroke, and subgroups produced confirmatory results. The 2024 ESC non-elevated 24-h PTTR, compared with the 2018 ESC/European Society of Hypertension non-hypertensive 24-h PTTR, shortened the interval required to reduce relative risk for adverse outcomes from 60% to 18% (14.4–4.3 h). Office BP, compared with 24-h PTTR, misclassified most participants with regard to BP control. Conclusions Longer time that ABP is within the 2024 ESC target range is associated with reduced adverse outcomes; PTTR derived from ABP refines risk prediction and compared with office BP avoids misclassification of individuals with regard to BP control.-
dc.description.sponsorshipBelgium: European Union (HEALTH-F7-305507 HOMAGE), European Research Council (Advanced Researcher Grant 2011-294713-EPLORE and Proof-of-Concept Grant 713601-uPROPHET), European Research Area Network on Cardiovascular Diseases (JTC2017-046-PROACT) and Research Foundation Flanders (G.0881.13); China: National Natural Science Foundation of China (grants 82100445, 82070432, and 82270469), Natural Science Foundation of Shanghai Municipality (22ZR1452900), and Shanghai Municipal Health Commission ‘Leading Academics’ (2022LJ022); Czech Republic: European Union (grants LSHM-CT-2006–037093 and HEALTH-F4-2007–201550) and Charles University Research Fund (projects P36 and Cooperation— Cardiovascular Science); Denmark: Danish Heart Foundation (grant 01-2-9-9A-22914) and Lundbeck Fonden (grant R32-A2740); Ireland: the Irish Allied Bank; Italy: European Union (grants LSHM-CT-2006– 037093 and HEALTH-F4-2007–201550); Japan: Ministry of Education, Culture, Sports, Science and Technology [JP19K19325, JP19K19466, JP19H03908, JP19K10662, JP20K08612, JP20K18819, JP21K10452, JP21K10478, JP21H04854, JP21K17313, JP21K19670, JP23K24616 (JP22H03358), JP22K10070, JP23K27855, JP23K09698, JP23K27855 (JP23H03165), JP23K07690, JP24K02656, and JP24K13469], the internal research grants from Keio University, Japan Arteriosclerosis Prevention Fund, Ministry of Health, Labor, and Welfare, Japan (H29– Junkankitou–Ippan–003 and 20FA1002), ACRO Incubation Grants of Teikyo University, Academic Contributions from Pfizer Japan Inc. and Bayer Yakuhin, Ltd, Scholarship donations from Daiichi Sankyo Co., Ltd, research support from Astellas Pharma Inc. and Takeda Pharmaceuticals Co., Ltd., Health Science Center Research Grant, Takeda Science Foundation, and Mochida Memorial Foundation for Medical and Pharmaceutical Research; Poland (Gdańsk): European Union (grants LSHM-CT-2006–037093 and HEALTH-F4-2007– 201550); Poland (Kraków): European Union (grants LSHM-CT-2006– 037093 and HEALTH-F4-2007–201550) and Foundation for Polish Science; Russian Federation: European Union (grants LSHM-CT-2006– 037093 and HEALTH-F4-2007–201550) and RAS State Target (grant FWNR-2024-0002); Spain: Fondo de Investigación Sanitaria (grant PI19/00665 and PI22/1164) (Instituto de Salud Carlos III and FEDER/ FSE); Uruguay: Asociación Española Primera en Salud; and Venezuela: The National Institute of Aging and the Fogarty International Center (grant 1–R01AG036469 A1), the National Institutes of Health and National Institute of Aging (grant 1 R03 AG054186-01), FONACIT, Caracas (grant G-97000726), and FundaConCiencia, Maracaibo (grant LOCTI). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The non-profit research institute Alliance for the Promotion of Preventive Medicine (URL: www.appremed.org) received a non- binding grant from OMRON Healthcare Co., Ltd., Kyoto, Japan. The Guangci Laureate Professorship of J.A.S. is supported by the Guangci Deep Mind Project of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.-
dc.language.isoen-
dc.rightsThe Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.-
dc.subject.otherAmbulatory blood pressure-
dc.subject.otherGuidelines-
dc.subject.other• Morbidity-
dc.subject.other• Mortality-
dc.subject.other• Population science-
dc.subject.other• Risk stratification-
dc.titleAmbulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis-
dc.typeJournal Contribution-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.statusEarly view-
dc.identifier.doi10.1093/eurheartj/ehaf220-
dc.identifier.isi001470308800001-
local.provider.typeCrossRef-
local.uhasselt.internationalyes-
item.contributorZhang, Dong-Yan-
item.contributorAn, De-Wei-
item.contributorYu, Yu-Ling-
item.contributorMelgarejo, Jesus D-
item.contributorBoggia, José-
item.contributorHansen, Tine W-
item.contributorMARTENS, Dries-
item.contributorAsayama, Kei-
item.contributorOhkubo, Takayoshi-
item.contributorStolarz-Skrzypek, Katarzyna-
item.contributorMalyutina, Sofia-
item.contributorCasiglia, Edoardo-
item.contributorLind, Lars-
item.contributorMaestre, Gladys E-
item.contributorWang, Ji-Guang-
item.contributorImai, Yutaka-
item.contributorKawecka-Jaszcz, Kalina-
item.contributorSandoya, Edgardo-
item.contributorRajzer, Marek-
item.contributorNAWROT, Tim-
item.contributorO’Brien, Eoin-
item.contributorYang, Wen-Yi-
item.contributorFilipovský, Jan-
item.contributorGraciani, Auxiliadora-
item.contributorBanegas, José R-
item.contributorLi, Yan-
item.contributorStaessen, Jan A-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
item.fullcitationZhang, Dong-Yan; An, De-Wei; Yu, Yu-Ling; Melgarejo, Jesus D; Boggia, José; Hansen, Tine W; MARTENS, Dries; Asayama, Kei; Ohkubo, Takayoshi; Stolarz-Skrzypek, Katarzyna; Malyutina, Sofia; Casiglia, Edoardo; Lind, Lars; Maestre, Gladys E; Wang, Ji-Guang; Imai, Yutaka; Kawecka-Jaszcz, Kalina; Sandoya, Edgardo; Rajzer, Marek; NAWROT, Tim; O’Brien, Eoin; Yang, Wen-Yi; Filipovský, Jan; Graciani, Auxiliadora; Banegas, José R; Li, Yan & Staessen, Jan A (2025) Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis. In: European heart journal,.-
crisitem.journal.issn0195-668X-
crisitem.journal.eissn1522-9645-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
ehaf220.pdfEarly view2.5 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.